RSV Vaccine Guidance for Older Adults | RSV | CDC
WEBWhat to know. CDC recommends a single dose of any FDA-licensed RSV vaccine for all adults ages 75 and older and adults ages 60–74 at increased risk of severe RSV. Three RSV vaccines are currently available for adults ages 60 and older: GSK’s Arexvy, Moderna’s mResvia, and Pfizer’s Abrysvo. Eligible older adults may receive any of the ...
Healthcare Providers: RSV Vaccination for Adults 60 Years of Age …
WEBConsult the package insert for proper storage and handling details, shelf life, and reconstitution instructions: Package Insert – AREXVY (fda.gov). In June 2024, FDA licensed AREXVY for use in people ages 50–59 who are at increased risk of RSV lower respiratory tract disease.
ACIP Evidence to Recommendations for Use of GSK Adjuvanted …
WEBSep 5, 2024 · Review ACIP recommendations for use of GSK adjuvanted RSVPreF3 vaccine (AREXVY) in adults ages 60 and older. Review ACIP recommendations for use of GSK adjuvanted RSVPreF3 vaccine (AREXVY) in adults ages 60 an ... CDC estimates that hospitalization incidence among adults 65 and older was approximately 2-fold to 3-fold higher than among adults ...
New data for AREXVY, GSK’s RSV vaccine, show potential to help …
WEBOct 25, 2023 · AREXVY contains recombinant respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01 E adjuvant.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
US FDA approves expanded age indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
US Centers for Disease Control and Prevention’s Advisory ... - GSK
WEBUS Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making. Launch is planned in the US before the 2023 RSV season.
US Centers for Disease Control and Prevention’s Advisory ... - GSK
WEBJun 22, 2023 · US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend Arexvy for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making. Launch is planned in the US before the 2023 RSV season.
ACIP Evidence to Recommendations for Use of Protein Subunit …
WEBSep 5, 2024 · Learn more about the ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease. ... CDC fields questions about vaccination status, intent, knowledge, attitudes, …
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time. The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy ...
- Some results have been removed